Myobloc (Diacerein)

Diacerein, the active ingredient in Myobloc, is a disease-modifying osteoarthritis drug (DMOAD) presented as an oral formulation for oral use. It is indicated for the management of osteoarthritis of the knee and hip, providing symptomatic relief and slowing cartilage degradation in adult patients.

GNH USA supplies Myobloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myobloc is a disease‑modifying osteoarthritis drug that targets joint degeneration pathways.

- Osteoarthritis of knee: reduces pain and slows cartilage loss, improving joint function. - Osteoarthritis of hip: alleviates discomfort and helps preserve joint structure. - General osteoarthritis: provides symptomatic relief and may delay disease progression.

Adverse reactions may occur with oral diacerein therapy.

Common Side Effects: - Diarrhoea: loose stools occurring during early treatment. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of queasiness or urge to vomit. - Flatulence: excess intestinal gas. - Dyspepsia: indigestion or upper abdominal fullness. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Elevated liver enzymes: indicating possible hepatic stress. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare skin blistering condition. - Blood dyscrasias: abnormal blood cell counts. - Severe skin rash: extensive erythema or exfoliation.

Patients should be monitored for safety considerations before and during therapy.

- Liver function monitoring: check transaminases periodically. - Gastrointestinal caution: avoid in active ulcer disease. - Elderly use: start with lower dose and observe tolerance. - Renal impairment: adjust dose if kidney function is reduced. - Hypersensitivity: discontinue if allergic signs appear. - Store at below 25°C: keep in the original pack, protect from moisture.

Diacerein may interact with other medicines, requiring attention to co‑administration.

Major Interactions (Avoid): - NSAIDs: combined use increases risk of gastrointestinal bleeding. - Anticoagulants: may potentiate bleeding tendencies.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin): may reduce diacerein exposure. - Diuretics: monitor electrolyte balance. - Other DMOADs: assess additive effects on liver function. - Antacids: may affect absorption if taken simultaneously.